GlassScriptPhysician profile
Priya V Desai
NPI 1750414157
$9,680.76
in general payments reported to CMS, 2019-2025
26 companies · $3,683 in 2025
The $3,683 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $158 · 2021: $1,135 · 2022: $1,296 · 2023: $1,097 · 2024: $1,855 · 2025: $3,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,378 · Consulting Fee: $2,250 · Travel and Lodging: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,378.39 |
| Consulting Fee | $2,250.00 |
| Travel and Lodging | $1,006.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,696.36 | 2023-2025 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Idosetr, Idose |
| Onmark, INC. | $1,655.74 | 2025 | |
| Rxsight INC | $1,340.83 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Allergan, INC. | $1,143.89 | 2019-2022 | |
| Eyepoint US, INC. | $1,122.13 | 2019-2021 | |
| Sight Sciences, INC. | $565.12 | 2019-2024 | Omni Surgical System |
| Abbvie INC. | $304.82 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb Americas INC. | $300.03 | 2022-2025 | Envista Mx60 Iol, Stellaris, Envista Aspire Iol |
| Oyster Point Pharma, INC. | $256.95 | 2023-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $232.49 | 2019-2023 | Cequa |
| Amgen INC. | $216.93 | 2025 | Tepezza |
| Alcon Vision LLC | $166.75 | 2022-2025 | Hydrus Microstent, Centurion, Clareon |
| Davol INC. | $132.17 | 2023 | Arista Ah Flexitip |
| Teva Pharmaceuticals USA, INC. | $117.99 | 2019 | |
| Apellis Pharmaceuticals, INC. | $101.93 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $63.62 | 2022 | |
| Shire North American Group INC | $43.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.23 | 2019-2022 | |
| Incyte Corporation | $33.65 | 2024 | Opzelura |
| Johnson & Johnson Surgical Vision, INC. | $32.23 | 2025 | Tecnis Iol |
| Ocular Therapeutix, INC. | $28.70 | 2021-2023 | Dextenza |
| Harrow Eye, LLC | $21.58 | 2025 | Vevye |
| Omeros Corporation | $19.54 | 2019 | |
| Genentech USA, INC. | $15.25 | 2023 | Vabysmo |
| Kala Pharmaceuticals, INC. | $14.03 | 2020 | |
| Horizon Therapeutics Plc | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.